Elebsiran sodium
Based on 1 Customer Validation
Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 95.83%
- 화학식: C485H658F9N158O294P39S6
- 분자량:14976.67 (free acid)
-
보관:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Elebsiran (0.1 pM-100 nM) sodium effectively reduces HBsAg and the infectivity of HDV, and when combined with Tobevibart (HY-P990015) for treatment, it shows an additive effect[1].
Elebsiran sodium exhibits comparable antiviral activity to ALN-HBV in HepG2.2.15 cells but its cytotoxicity is significantly reduced[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Elebsiran (12-100 mg/kg, s.c., 5 doses on Days 0, 21, 28, 35, and 42) sodium does not cause a significant increase in ALT in all dosage groups and demonstrates high liver safety in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HBV/HDV-coinfected liver-chimeric model established in liver-chimeric mice[1]
-
Dosage:9 mg/kg alone or with 15 mg/kg muHBC34 (the murinized version of Tobevibart)
-
Administration:Subcutaneous injection (s.c.), single dose
-
Result:Significant decreased of 0.6 log for HBsAg, 0.5 log for HBV DNA and 0.7 log for HDV RNA compared to the vehicle control on day 14 post-treatment.
Led to the strongest reductions in HBsAg, HBV DNA and HDV RNA levels relative to the vehicle group with muHBC34.
-
Animal Model:Chimeric mouse model established male PXB mice at 12 to 18 weeks[3]
-
Dosage:12 mg/kg, 36 mg/kg, and 100 mg/kg
-
Administration:Subcutaneous injection (s.c.), on Days 0, 21, 28, 35, and 42
-
Result:Observed a clear dose-dependent increase in hALT1 levels, whereas no relationship between hALT1 and dose level.
Chemical Information
-
Appearance Solid
-
분자량 14976.67 (free acid)
-
화학식 C485H658F9N158O294P39S6
-
Color White to off-white
-
SMILES
[Elebsiran sodium]
-
Synonyms
VIR-2218 sodium
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
용액&용해도
H2O : ≥ 100 mg/mL
* "≥" means soluble, but saturation unknown.
순도&문서
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Zhou J, et al. Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection. JHEP Rep. 2025 Mar 22;7(6):101400. [Content Brief]
[2]. Gupta SV, et al. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs R D. 2021 Dec;21(4):455-465. [Content Brief]
[3]. Ji Y, et al. The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses. Gastroenterology. 2025 Jul;169(1):136-149. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)